CONNECTED TRANSACTION - ACQUISITION OF 5% EQUITY INTEREST IN CT TIANQING THROUGH THE ACQUISITION OF EQUITY INTERESTS IN THE TARGET COMPANY

VOLUNTARY ANNOUNCEMENT - TQH5528 “ORAL STAT6 DEGRADER” PRECLINICAL STUDY DATA PRESENTED AT ERS 2026

VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL DATA FOR TQC3721 INHALED POWDER FORMULATION, A "PDE3/4 INHIBITOR", PRESENTED AT ERS 2026

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQB6426 "GPC3 ADC" APPROVED BY FDA

NEXT DAY DISCLOSURE RETURN

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2026

VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR TQB2102 WITH CIPLA

VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I CLINICAL TRIAL OF KYLO-11 “LPA SIRNA” PRESENTED AT ESC 2026 AND PUBLISHED IN THE LANCET